BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Prognosis
303 results:

  • 1. UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/akt activation.
    Wang L; Zhao S; Wang Y; Liu J; Wang X
    BMC Cancer; 2024 Apr; 24(1):497. PubMed ID: 38637730
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Decoding the tumour-modulatory roles of LIMK2.
    Chong ZX; Ho WY; Yeap SK
    Life Sci; 2024 Jun; 347():122609. PubMed ID: 38580197
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Pan-cancer analysis of DDIT4 identifying its prognostic value and function in acute myeloid leukemia.
    Li F; Miao J; Liu R; Zhang R; He A
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):144. PubMed ID: 38507057
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
    Li X; Gao F; Meng X; Zhang X; Sun C; Liu H; Yu J; Liu X; Han X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Golchehre Z; Chavoshzadeh Z; Ren X; Wang X; Zhang H
    Br J Haematol; 2024 May; 204(5):1771-1779. PubMed ID: 38447995
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations.
    Wang Z; Lu X; Liu C; Huang F; Lu T; Chen Y; Liu L; Lu S
    Eur J Med Chem; 2024 Mar; 268():116237. PubMed ID: 38387337
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
    Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
    Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Gu H; Chen C; Hou ZS; He XD; Xie S; Ni J; Qian C; Cheng X; Jiang T; Yang C; Roberts TM; Zheng J; Varner JA; Armstrong SA; Zhao JJ
    Blood; 2024 May; 143(19):1965-1979. PubMed ID: 38271660
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The Potential Transcriptomic and Metabolomic Mechanisms of ATO and ATRA in Treatment of FLT3-ITD Acute Myeloid leukemia.
    Peng CJ; Fan Z; Luo JS; Wang LN; Li Y; Liang C; Zhang XL; Luo XQ; Huang LB; Tang YL
    Technol Cancer Res Treat; 2024; 23():15330338231223080. PubMed ID: 38179723
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Inhibition of PI3K-akt-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells.
    Şansaçar M; Sağır H; Gencer Akçok EB
    Med Oncol; 2023 Dec; 41(1):31. PubMed ID: 38148433
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
    Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.
    Zhang S; Yan J; He L; Jiang Z; Jiang H
    Cancer Gene Ther; 2024 Mar; 31(3):484-494. PubMed ID: 38135698
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
    Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
    Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC.
    Zheng SX; Chen J; Zhuang BB; Zhang Q; Shi SS; Zhang GL
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16055-16067. PubMed ID: 37695389
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia.
    Carlock C; Bai Y; Paige-Hood A; Li Q; Nguele Meke F; Zhang ZY
    JCI Insight; 2023 Oct; 8(19):. PubMed ID: 37665633
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia.
    Xie C; Zhou H; Qin D; Zheng H; Tang Y; Li W; Zhou J; Liu L; Yu X; Duan H; Zhou Y; Li Z; Fang Z; Luo Y; Carter BZ; Xu B; Zha J
    Cell Death Dis; 2023 Aug; 14(8):573. PubMed ID: 37644011
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Expression and Alteration Value of Long Noncoding RNA AB073614 and FER1L4 in Patients with Acute Myeloid leukemia (AML).
    Ganji A; Khosravi M; Mosayebi G; Gholami M; Ghazavi A; Keshavarzian N; Sayyadi M
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2271-2277. PubMed ID: 37505756
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses leukemia Growth in a T-ALL Xenotransplantation Mouse Model.
    Ehm P; Rietow R; Wegner W; Bußmann L; Kriegs M; Dierck K; Horn S; Streichert T; Horstmann M; Jücker M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443832
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
    Song X; Qi J; Li X; Zhou M; He J; Chu T; Han Y
    Platelets; 2023 Dec; 34(1):2229905. PubMed ID: 37409458
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia.
    Villa-Morales M; Pérez-Gómez L; Pérez-Gómez E; López-Nieva P; Fernández-Navarro P; Santos J
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373496
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
    Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
    Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 16.